VivoSim Labs (VIVS) said Wednesday it received a $5 million milestone payment from Eli Lilly (LLY) after the first patient was dosed in a phase 2 trial of a drug acquired by Eli Lilly.
VivoSim said it remains eligible for up to an additional $45 million in milestone payments tied to future regulatory and commercial milestones.
In addition, the company said it expects fiscal 2027 revenue to grow more than 500%, driven by demand for its new approach methodologies 3d human cellular models for preclinical safety.
VivoSim Labs shares were up more than 71% in premarket activity Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments